SynAct Pharma AB (OSTO:SYNACT) EPS without NRI: kr-49.66 (TTM As of Mar. 2026)


OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
19 GF Score
Price kr21.80
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB EPS without NRI?

SynAct Pharma AB OSTO:SYNACT +2.11% 19 EPS without NRI is kr-49.66 as of Mar. 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,167 Biotechnology companies, SynAct Pharma AB ranks worse than 51.76% on this metric.

SynAct Pharma AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was kr-48.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was kr-49.66.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for SynAct Pharma AB's EPS without NRI or its related term are showing as below:

OSTO:SYNACT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -79.4   Med: -7.7   Max: 15.3
Current: 15.3

OSTO:SYNACT's 3-Year EPS without NRI Growth Rate is ranked worse than
51.76% of 1167 companies
in the Biotechnology industry
Industry Median: 16.2 vs OSTO:SYNACT: 15.30

SynAct Pharma AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-48.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-49.66.

SynAct Pharma AB's EPS (Basic) for the three months ended in Mar. 2026 was kr-0.48. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-2.14.


SynAct Pharma AB  (OSTO:SYNACT) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


SynAct Pharma AB EPS without NRI Related Terms


SynAct Pharma AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB EPS without NRI Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.66 -3.57 -6.73 -2.08 -2.17

SynAct Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.56 -0.67 -0.43 -48.00

OSTO:SYNACT vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, SynAct Pharma AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's PE Ratio without NRI falls into.


OSTO:SYNACT
19GF Score
SynAct Pharma AB OSTO:SYNACT
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-49.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of kr-49.66 mean?
SynAct Pharma AB (OSTO:SYNACT) has a EPS without NRI of kr-49.66 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on SynAct Pharma AB and its competitors. According to the industry distribution chart, SynAct Pharma AB ranks #604 out of 1167 companies in the Biotechnology industry, placing it in the top 51.8%.
Is SynAct Pharma AB's EPS without NRI too high?
SynAct Pharma AB's current EPS without NRI is kr-49.66. Based on the distribution chart, SynAct Pharma AB ranks #604 out of 1167 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SynAct Pharma AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SynAct Pharma AB ranks #604 out of 1167 companies for EPS without NRI. This places SynAct Pharma AB in the lower half of its industry. The industry median EPS without NRI is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on SynAct Pharma AB and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SynAct Pharma AB's current EPS without NRI is kr-49.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current EPS without NRI of kr-49.66. The current EPS without NRI is kr-49.66. SynAct Pharma AB's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current EPS without NRI is kr-49.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
19GF Score

Get the complete analysis for OSTO:SYNACT

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr21.80
Price